Kisspeptin Held Its Effect for Twelve Days — But Only When It Was Switched Off Each Night

Most writing about kisspeptin asks what it does. A paper published in the European Journal of Endocrinology in August 2026, from the Section of Endocrinology and Investigative Medicine at Imperial College London, asks something narrower and more useful: when. Its answer is that the timing, not the amount, decided whether anything kept happening.

What kisspeptin-10 is, and where it sits

Kisspeptin is a natural peptide that acts on a receptor called KISS1R. Kisspeptin-10 is a ten-amino-acid fragment of it. In the hypothalamus, kisspeptin signalling sits one step upstream of gonadotropin-releasing hormone, which drives the pituitary to release two gonadotropins — luteinising hormone (LH) and follicle-stimulating hormone (FSH) — which in turn drive testosterone. So kisspeptin is a lever on the top of that chain rather than a hormone that acts on the tissues at the bottom of it.

What was actually done

The study was randomised, single-blinded and placebo-controlled. Fifteen healthy men took part across three separate experiments (seven, four and seven participants), with twelve men serving as controls. The measured endpoints were LH, FSH and testosterone — hormone concentrations in blood, nothing else.

The three experiments were:

• an acute eight-hour run at escalating amounts,
• continuous delivery for five days,
• and eight hours a day, sixteen hours off, for twelve days.

The three results, in order

Acute. LH, FSH and testosterone all rose in proportion to the amount infused, compared with vehicle (P < .0001). That part was expected.

Five days continuous. Testosterone concentrations remained elevated — but LH and FSH were back to vehicle levels. The gonadotropin response had faded while the downstream hormone had not yet followed it down.

Twelve days, eight hours on. LH stayed above vehicle for the whole twelve days. The reported mean LH change was −0.16 ± 0.19 for vehicle, +1.68 ± 0.25 on day 1, and +1.14 ± 0.33 on day 12 (P = .003 versus vehicle).

Read that last line carefully, because it is easy to over-read. Day 12 is lower than day 1. The response was sustained, not unchanged. Something still attenuated over twelve days, just much less than it did under continuous delivery.

The receptor did not stop working

After the twelve days, a single bolus still produced a gonadotropin rise. The authors read this as the kisspeptin receptor remaining functional.

That distinction matters. The fading of a response to a compound given without a break has a name — tachyphylaxis — and the usual explanation offered for it is that the receptor has been downregulated or lost. Here, it had not been. Whatever caused the fade under continuous delivery left the receptor able to respond to a fresh stimulus, which points at the circuit adapting rather than the receptor going away.

What this study is not

• Hormone concentrations are not fertility, not conception, not symptom relief. No clinical outcome was measured.
• Fifteen participants in total, split across three experiments, the smallest of which had four.
• Single-blinded, not double-blinded.
• Healthy men only. Nothing here speaks to women, or to patients with a diagnosis.

The authors' own framing is the right one: these data "can inform development of chronic kisspeptin administration protocols for the treatment of reproductive disorders." That is a sentence about designing a future trial. It is not a trial result.

Where the registered work stands

The published work sits inside a study registered as NCT02081924 at Imperial College London, listed with an enrolment target of 76 and a start date in April 2014. It is still recruiting, its primary completion date is now listed as November 2027, and no results have been posted to the registry.

Separately, at Massachusetts General Hospital, two phase 2 studies are recruiting in patients rather than healthy volunteers. NCT05896293, in idiopathic hypogonadotropic hypogonadism, lists 36 participants, a start date of February 2023, a primary completion date of May 2028, and funding from the FDA Office of Orphan Products Development. Its primary endpoint is the change in LH pulse amplitude across two weeks; its secondary endpoint is the proportion of female participants reaching a mature follicle or showing evidence of ovulation. A second study, NCT07224438, in hypothalamic amenorrhea, lists 20 participants and a start date in December 2025.

Our standing position applies here as it did last week: a registry entry is a filing, not a verified study, and none of these has posted a result. What makes them worth naming is that they are in patients with a defined diagnosis and they carry an endpoint that is clinical rather than hormonal — which the published work does not.

Why the nuance is the whole story

A narrative review in Sexual Medicine Reviews, published in September 2026, surveyed peptides used in urology and sexual medicine and placed kisspeptin as showing early promise while remaining investigational. The Imperial finding is exactly the kind of result that gets flattened on its way out of the literature. "Kisspeptin kept working for twelve days" is true. It also drops the only thing the study was built to test — that running it continuously did not.

What has not been established

• No published human study of kisspeptin-10 has reported a fertility or other clinical outcome.
• The on-off schedule has not been tested in women, or in patients with a reproductive diagnosis.
• Long-term human safety is uncharacterised. The longest published exposure in this work is twelve days.
• Whether the partial attenuation visible by day 12 continues, stabilises or reverses beyond twelve days was not tested.

What to watch

The two Massachusetts General Hospital phase 2 studies. LH pulse amplitude after two weeks is a mechanistic endpoint of the same kind the Imperial work already reports. The ovulation endpoint is not. That second number, if it is ever posted, is the one that would move kisspeptin out of the investigational column.

Sources

1. Yeung AC, Phylactou M, Koysombat K, et al. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol (2026)
2. ClinicalTrials.gov NCT02081924 — Reproductive Hormones During Sustained Administration of Kisspeptin (Imperial College London)
3. ClinicalTrials.gov NCT05896293 — Kisspeptin Administration to Patients With IHH, phase 2 (Massachusetts General Hospital)
4. Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev (2026)

Compounds in this article

Kisspeptin-10